JURY FINDS FOR DOW  DOW IN BIRTH DEFECT CASE PHILADELPHIA FEB 26 DOW CHEMICAL CO'S  DOW MERRELL DOW PHARMACEUTICALS INC UNIT SAID A JURY FOUND THAT BENDECTIN DID NOT CAUSE THE BIRTH DEFECTS OF A SEVEN YEAR OLD BOY WHOSE MOTHER TOOK THE DRUG DURING PREGNANCY THE ANTI NAUSEA DRUG HAS BEEN USED TO TREAT MORNING  SICKNESS AND WAS DISCONTINUED IN 1983 AMID ALLEGATIONS THAT THE DRUG CAUSED BIRTH DEFECTS MERRELL SAID THAT TO DATE THERE HAVE BEEN 12 OTHER TRIALS INVOLVING THE DRUG 10 IN THE US AND TWO IN WEST GERMANY IT SAID VERDICTS OR JUDGEMENTS IN FAVOR OF THE COMPANY WERE OBTAINED IN EIGHT OF THE TRIALS ONE OF WHICH INCLUDED ABOUT 1150 PLAINTIFFS IN TWO TRIALS MERRELL SAID VERDICTS WERE IN FAVOR OF THE PLAINTIFFS IN ONE IT SAID THE TRIAL JUDGE OVERRULED THE JURY'S VERDICT AND ISSUED A JUDGEMENT IN FAVOR OF THE COMPANY AND A THREE JUDGE PANEL OF THE COURT OF APPEALS OVERTURNED THE TRIAL JUDGE'S RULING MERRELL IS NOW AWAITING A REHEARING OF THIS CASE BY THE FULL COURT OF APPEALS OF THE REMAINING TWO TRIALS ONE ENDED IN A MISTRIAL AND IN THE OTHER THE JURY WAS UNABLE TO REACH A VERDICT AT ONE POINT ABOUT 1700 LAWSUITS HAD BEEN FILED ALLEGING THE DRUG CAUSED BIRTH DEFECTS SAID A COMPANY SPOKESMAN HE SAID ABOUT 300 LAWSUITS ARE PENDING BENDECTIN WAS FIRST INTRODUCED IN THE EARLY 1950S AND THE MERRELL SPOKESMAN SAID A VALID APPLICATION TO MAKE AND MARKET THE DRUG IS WITH THE FOOD AND DRUG ADMINISTRATION SHOULD THE COMPANY DECIDE IT WANTS TO REINTRODUCE IT  